MARKET

ONCY

ONCY

Oncolytics Biotech Inc
NASDAQ
0.4116
+0.0298
+7.81%
After Hours: 0.4114 -0.0002 -0.05% 19:56 11/11 EST
OPEN
0.3980
PREV CLOSE
0.3818
HIGH
0.4191
LOW
0.3669
VOLUME
1.50M
TURNOVER
--
52 WEEK HIGH
1.300
52 WEEK LOW
0.3669
MARKET CAP
53.97M
P/E (TTM)
-1.2802
1D
5D
1M
3M
1Y
5Y
1D
Oncolytics enters clinical supply agreement with Coherus Oncology
TipRanks · 9h ago
Oncolytics Biotech Inc. Announces Translational Data for Pelareorep in Multiple Myeloma to be Presented at 68th ASH Annual Meeting
NASDAQ · 2d ago
Pelareorep Data Show Enhanced Immune Activity in Multiple Myeloma
TipRanks · 2d ago
Oncolytics: Pelareorep induces coordinated immune responses in MM patients
TipRanks · 2d ago
Weekly Report: what happened at ONCY last week (1102-1106)?
Weekly Report · 2d ago
Oncolytics Biotech Inc. Announces Translational Data for Pelareorep at SITC 2026 Annual Meeting
NASDAQ · 11/04 22:12
H.C. Wainwright Sticks to Their Buy Rating for Oncolytics Biotech (ONCY)
TipRanks · 11/04 17:46
Oncolytics Biotech Reports Pelareorep Immune Activation in Anal Cancer
TipRanks · 11/04 14:57
More
About ONCY
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The Company is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

Webull offers Oncolytics Biotech Inc stock information, including NASDAQ: ONCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ONCY stock methods without spending real money on the virtual paper trading platform.